Jan 14 (Reuters) - Gilead Sciences Inc has notified the U.S. health regulator of its decision to voluntarily withdraw the use of its drug Zydelig for two types of cancer - follicular lymphoma and small lymphocytic leukemia. (Reporting by Leroy Leo in Bengaluru; Editing by Arun Koyyur)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
69.45 USD | +0.20% | +1.32% | -14.34% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.34% | 86.35B | |
+55.35% | 811B | |
+43.96% | 640B | |
-6.38% | 353B | |
+19.49% | 333B | |
+9.78% | 302B | |
+17.23% | 246B | |
+2.66% | 225B | |
+12.85% | 218B | |
+9.16% | 168B |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.
- Gilead withdraws use of Zydelig to treat two types of cancer